Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs JetBlue Airways Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while JetBlue Airways Corporation trades at $5.9 (market cap $2.14B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 18.6× JetBlue Airways Corporation's market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | JBLU | |
|---|---|---|
Market Cap | $39.89B | $2.14B |
Sector | Health | Industrials |
52-Week High | $491.22 | $6.46 |
52-Week Low | $278.09 | $4.03 |
Enterprise Value | $38.15B | $9.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
JetBlue (JBLU) trades at $5.76, down 2.7% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported a net loss of $602 million in 2025, with negative profit margins and elevated debt levels. Recent news highlights a major Fort Lauderdale expansion, while analyst consensus is predominantly Hold with a $5.12 price target below the current price.
The outlook remains challenging due to persistent losses and high leverage, though expansion efforts and potential fuel cost relief offer some upside. Key risks include volatile oil prices, competitive pressure, and execution of the turnaround strategy. Investors should weigh cost management improvements against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
